{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:37:24Z","timestamp":1788280644457,"version":"build-2803163510"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T00:00:00Z","timestamp":1610323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T00:00:00Z","timestamp":1610323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although identified as the key environmental driver of common cutaneous melanoma, the role of ultraviolet radiation (UVR)-induced DNA damage in mucosal melanoma is poorly defined. We analyze 10 mucosal melanomas of conjunctival origin by whole genome sequencing and our data shows a predominance of UVR-associated single base substitution signature 7 (SBS7) in the majority of the samples. Our data shows mucosal melanomas with SBS7 dominance have similar genomic patterns to cutaneous melanomas and therefore this subset should not be excluded from treatments currently used for common cutaneous melanoma.<\/jats:p>","DOI":"10.1038\/s41467-020-20432-5","type":"journal-article","created":{"date-parts":[[2021,1,11]],"date-time":"2021-01-11T11:25:44Z","timestamp":1610364344000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Ultraviolet radiation drives mutations in a subset of mucosal melanomas"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7769-2939","authenticated-orcid":false,"given":"Piyushkumar A.","family":"Mundra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Dhomen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5443-0802","authenticated-orcid":false,"given":"Manuel","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4110-6739","authenticated-orcid":false,"given":"Lauge Hjorth","family":"Mikkelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Cassoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Valpione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2969-3173","authenticated-orcid":false,"given":"Jorge S.","family":"Reis-Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Heegaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8100-2272","authenticated-orcid":false,"given":"Marc-Henri","family":"Stern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Roman-Roman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7484-4183","authenticated-orcid":false,"given":"Richard","family":"Marais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,11]]},"reference":[{"key":"20432_CR1","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1146\/annurev-pathol-012513-104658","volume":"9","author":"BC Bastian","year":"2014","unstructured":"Bastian, B. C. The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu. Rev. Pathol. 9, 239\u2013271 (2014).","journal-title":"Annu. Rev. Pathol."},{"key":"20432_CR2","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ccell.2017.07.003","volume":"32","author":"AG Robertson","year":"2017","unstructured":"Robertson, A. G. et al. Integrative analysis identifies four molecular and clinical subsets in uveal melanoma. Cancer Cell 32, 204\u2013220 e215 (2017).","journal-title":"Cancer Cell"},{"key":"20432_CR3","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/s41591-018-0265-6","volume":"25","author":"LD Trucco","year":"2019","unstructured":"Trucco, L. D. et al. Ultraviolet radiation-induced DNA damage is prognostic for outcome in melanoma. Nat. Med. 25, 221\u2013224 (2019).","journal-title":"Nat. Med."},{"key":"20432_CR4","doi-asserted-by":"publisher","first-page":"MMT11","DOI":"10.2217\/mmt-2018-0003","volume":"5","author":"H Tyrrell","year":"2018","unstructured":"Tyrrell, H. & Payne, M. Combatting mucosal melanoma: recent advances and future perspectives. Melanoma Manag. 5, MMT11 (2018).","journal-title":"Melanoma Manag."},{"key":"20432_CR5","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/path.4204","volume":"230","author":"SJ Furney","year":"2013","unstructured":"Furney, S. J. et al. Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma. J. Pathol. 230, 261\u2013269 (2013).","journal-title":"J. Pathol."},{"key":"20432_CR6","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nature22071","volume":"545","author":"NK Hayward","year":"2017","unstructured":"Hayward, N. K. et al. Whole-genome landscapes of major melanoma subtypes. Nature 545, 175\u2013180 (2017).","journal-title":"Nature"},{"key":"20432_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11107-x","volume":"10","author":"F Newell","year":"2019","unstructured":"Newell, F. et al. Whole-genome landscape of mucosal melanoma reveals diverse drivers and therapeutic targets. Nat. Commun. 10, 3163 (2019).","journal-title":"Nat. Commun."},{"key":"20432_CR8","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/apm.12529","volume":"124","author":"LH Mikkelsen","year":"2016","unstructured":"Mikkelsen, L. H. et al. Mucosal malignant melanoma - a clinical, oncological, pathological and genetic survey. APMIS 124, 475\u2013486 (2016).","journal-title":"APMIS"},{"key":"20432_CR9","doi-asserted-by":"publisher","first-page":"3548","DOI":"10.1158\/1078-0432.CCR-18-3442","volume":"25","author":"R Zhou","year":"2019","unstructured":"Zhou, R. et al. Analysis of mucosal melanoma whole-genome landscapes reveals clinically relevant genomic aberrations. Clin. Cancer Res. 25, 3548\u20133560 (2019).","journal-title":"Clin. Cancer Res."},{"key":"20432_CR10","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415\u2013421 (2013).","journal-title":"Nature"},{"key":"20432_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16276-8","volume":"11","author":"PA Johansson","year":"2020","unstructured":"Johansson, P. A. et al. Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours. Nat. Commun. 11, 2408 (2020).","journal-title":"Nat. Commun."},{"key":"20432_CR12","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/jhg.2015.152","volume":"61","author":"C Rivolta","year":"2016","unstructured":"Rivolta, C. et al. UV light signature in conjunctival melanoma; not only skin should be protected from solar radiation. J. Hum. Genet. 61, 361\u2013362 (2016).","journal-title":"J. Hum. Genet."},{"key":"20432_CR13","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1158\/1078-0432.CCR-13-0163","volume":"19","author":"KG Griewank","year":"2013","unstructured":"Griewank, K. G. et al. Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas. Clin. Cancer Res. 19, 3143\u20133152 (2013).","journal-title":"Clin. Cancer Res."},{"key":"20432_CR14","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1001\/jamaophthalmol.2017.4837","volume":"135","author":"SS Swaminathan","year":"2017","unstructured":"Swaminathan, S. S. et al. Molecular characteristics of conjunctival melanoma using whole-exome sequencing. JAMA Ophthalmol. 135, 1434\u20131437 (2017).","journal-title":"JAMA Ophthalmol."},{"key":"20432_CR15","doi-asserted-by":"publisher","first-page":"40683","DOI":"10.18632\/oncotarget.16542","volume":"8","author":"I Cosgarea","year":"2017","unstructured":"Cosgarea, I. et al. Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations. Oncotarget 8, 40683\u201340692 (2017).","journal-title":"Oncotarget"},{"key":"20432_CR16","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1097\/CCO.0b013e32833888ee","volume":"22","author":"KT Flaherty","year":"2010","unstructured":"Flaherty, K. T., Hodi, F. S. & Bastian, B. C. Mutation-driven drug development in melanoma. Curr. Opin. Oncol. 22, 178\u2013183 (2010).","journal-title":"Curr. Opin. Oncol."},{"key":"20432_CR17","doi-asserted-by":"publisher","first-page":"9000","DOI":"10.1200\/jco.2009.27.15_suppl.9000","volume":"27","author":"K Flaherty","year":"2009","unstructured":"Flaherty, K. et al. Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J. Clin. Oncol. 27, 9000\u20139000 (2009).","journal-title":"J. Clin. Oncol."},{"key":"20432_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2657-7","volume":"16","author":"A Maleka","year":"2016","unstructured":"Maleka, A., Astrom, G., Bystrom, P. & Ullenhag, G. J. A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib. BMC Cancer 16, 634 (2016).","journal-title":"BMC Cancer"},{"key":"20432_CR19","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber, J. et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N. Engl. J. Med. 377, 1824\u20131835 (2017).","journal-title":"N. Engl. J. Med."},{"key":"20432_CR20","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont, A. M. M. et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N. Engl. J. Med. 378, 1789\u20131801 (2018).","journal-title":"N. Engl. J. Med."},{"key":"20432_CR21","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521\u20132532 (2015).","journal-title":"N. Engl. J. Med."},{"key":"20432_CR22","doi-asserted-by":"publisher","first-page":"1908065","DOI":"10.1155\/2018\/1908065","volume":"2018","author":"C Mignard","year":"2018","unstructured":"Mignard, C. et al. Efficacy of immunotherapy in patients with metastatic mucosal or uveal melanoma. J. Oncol. 2018, 1908065 (2018).","journal-title":"J. Oncol."},{"key":"20432_CR23","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ejca.2019.07.010","volume":"119","author":"P Nathan","year":"2019","unstructured":"Nathan, P. et al. Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). Eur. J. Cancer 119, 168\u2013178 (2019).","journal-title":"Eur. J. Cancer"},{"key":"20432_CR24","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1001\/jamaophthalmol.2018.3488","volume":"136","author":"O Sagiv","year":"2018","unstructured":"Sagiv, O. et al. Immunotherapy With programmed cell death 1 inhibitors for 5 patients with conjunctival melanoma. JAMA Ophthalmol. 136, 1236\u20131241 (2018).","journal-title":"JAMA Ophthalmol."},{"key":"20432_CR25","doi-asserted-by":"publisher","first-page":"930","DOI":"10.18632\/oncotarget.26584","volume":"10","author":"C Quek","year":"2019","unstructured":"Quek, C. et al. Recurrent hotspot SF3B1 mutations at codon 625 in vulvovaginal mucosal melanoma identified in a study of 27 Australian mucosal melanomas. Oncotarget 10, 930\u2013941 (2019).","journal-title":"Oncotarget"},{"key":"20432_CR26","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/modpathol.2016.179","volume":"30","author":"HM Yang","year":"2017","unstructured":"Yang, H. M. et al. Identification of recurrent mutational events in anorectal melanoma. Mod. Pathol. 30, 286\u2013296 (2017).","journal-title":"Mod. Pathol."},{"key":"20432_CR27","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1073\/pnas.0909738107","volume":"107","author":"AM Klein","year":"2010","unstructured":"Klein, A. M., Brash, D. E., Jones, P. H. & Simons, B. D. Stochastic fate of p53-mutant epidermal progenitor cells is tilted toward proliferation by UV B during preneoplasia. Proc. Natl Acad. Sci. USA 107, 270\u2013275 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"20432_CR28","doi-asserted-by":"publisher","first-page":"3414","DOI":"10.1158\/0008-5472.CAN-03-3249","volume":"64","author":"CC Maley","year":"2004","unstructured":"Maley, C. C. et al. Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett\u2019s esophagus. Cancer Res. 64, 3414\u20133427 (2004).","journal-title":"Cancer Res."},{"key":"20432_CR29","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. et al. The Sequence Alignment\/Map format and SAMtools. Bioinformatics 25, 2078\u20132079 (2009).","journal-title":"Bioinformatics"},{"key":"20432_CR30","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754\u20131760 (2009).","journal-title":"Bioinformatics"},{"key":"20432_CR31","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1101\/gr.107524.110","volume":"20","author":"A McKenna","year":"2010","unstructured":"McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297\u20131303 (2010).","journal-title":"Genome Res."},{"key":"20432_CR32","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nbt.2514","volume":"31","author":"K Cibulskis","year":"2013","unstructured":"Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213\u2013219 (2013).","journal-title":"Nat. Biotechnol."},{"key":"20432_CR33","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41592-018-0051-x","volume":"15","author":"S Kim","year":"2018","unstructured":"Kim, S. et al. Strelka2: fast and accurate calling of germline and somatic variants. Nat. Methods 15, 591\u2013594 (2018).","journal-title":"Nat. Methods"},{"key":"20432_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-0974-4","volume":"17","author":"W McLaren","year":"2016","unstructured":"McLaren, W. et al. The ensembl variant effect predictor. Genome Biol. 17, 122 (2016).","journal-title":"Genome Biol."},{"key":"20432_CR35","doi-asserted-by":"publisher","first-page":"i333","DOI":"10.1093\/bioinformatics\/bts378","volume":"28","author":"T Rausch","year":"2012","unstructured":"Rausch, T. et al. DELLY: structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics 28, i333\u2013i339 (2012).","journal-title":"Bioinformatics"},{"key":"20432_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-0893-4","volume":"17","author":"R Rosenthal","year":"2016","unstructured":"Rosenthal, R., McGranahan, N., Herrero, J., Taylor, B. S. & Swanton, C. DeconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. Genome Biol. 17, 31 (2016).","journal-title":"Genome Biol."},{"key":"20432_CR37","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1093\/annonc\/mdu479","volume":"26","author":"F Favero","year":"2015","unstructured":"Favero, F. et al. Sequenza: allele-specific copy number and mutation profiles from tumor sequencing data. Ann. Oncol. 26, 64\u201370 (2015).","journal-title":"Ann. Oncol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-20432-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-20432-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-20432-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T10:12:37Z","timestamp":1669975957000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-020-20432-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,11]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["20432"],"URL":"https:\/\/doi.org\/10.1038\/s41467-020-20432-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,11]]},"assertion":[{"value":"10 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.M. consultants for Pfizer, and as a former Institute of Cancer Research (London) employee, he may benefit from commercialized programs. J.S.R.F. consultants for Goldman Sachs, REPARE Therapeutics and Paige.AI, and serves on the scientific advisory boards of Volition Rx and Paige.AI, and ad hoc on the scientific advisory boards of Ventana Medical Systems, Roche Tissue Diagnostics, Genentech, Novartis, and InVicro. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"259"}}